1,4,7,10-Tetrakis(ethoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane

Catalog No. :
ACETPR029
CAS No. :
137076-50-7
Molecular Formula :
C24H44N4O8
Molecular Weight :
516.64

IUPAC Name:tetraethyl 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetate

1,4,7,10-Tetrakis(ethoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1,4,7,10-Tetrakis(ethoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane
IUPAC Nametetraethyl 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetate
MDL No.MFCD09263313
Molecular FormulaC24H44N4O8
Molecular Weight516.64
SMILESO=C(CN1CCN(CC(OCC)=O)CCN(CC(OCC)=O)CCN(CC(OCC)=O)CC1)OCC
InChI KeySHXTUKRRXWXLMI-UHFFFAOYSA-N
Synonymethyl 2-[4,7,10-tris(2-ethoxy-2-oxoethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;1,4,7,10-Tetrakis(ethoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane;DOTAET;1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, 1,4,7,10-tetraethyl ester;DOTAEt137076-50-7;1,4,7,10-Tetrakis(ethoxycarbonylmethyl)-1,4,7,10-tetraazacyc;tetraethyl 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetate;Doxorubicin Impurity 70 Hydrochloride
CAS No.137076-50-7

Synthetic Route by SureRoute

1. ACETPR029 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACDRKO719 route compound structure diagram
    ACDRKO719294-90-6 In Stock
  2. Then
  3. ACETPR029 route product structure diagram
    ACETPR029137076-50-7
Inquiry

2. ACETPR029 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACETPR029 route product structure diagram
    ACETPR029137076-50-7
Inquiry

Comments (0)